AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10103301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 275
Study 10103301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control intervention
Number of subjects: 275
Study 7551427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse described as 'a good researcher'
Number of subjects: 0
Study 7551427 — intervention group
Group type: COMPARATOR
Intervention: Nurse described as 'a good clinician'
Number of subjects: 0
Study 2200966 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolon 2 mg/kg/day IV initially, then prednisone orally for 3 weeks)
Number of subjects: 60
Study 2200966 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 60
Study 30795958 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free follow-up phase after stopping tenofovir disoproxil fumarate therapy
Number of subjects: 124
Study 30795958 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free follow-up phase for HBeAg-positive patients
Number of subjects: 124
Study 28847886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12275
Study 26346302 — intervention group
Group type: EXPERIMENTAL
Intervention: Food items (fish, pizza, chicken, cereals) and FADS1 rs174546 genotypes used as predictors in mathematical models.
Number of subjects: 1607
Study 23460845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo® Wii™ training
Number of subjects: 42
Study 23460845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training with the Nintendo® Wii™)
Number of subjects: 42
Study 22117658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Hypertension diet
Number of subjects: 828
Study 19770624 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg daily
Number of subjects: 44
Study 19770624 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 17449936 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent CABG
Number of subjects: 104
Study 15196292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous eletriptan (n = 24)
Number of subjects: 60
Study 15196292 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of sumatriptan (6 mg subcutaneously, n = 18)
Number of subjects: 60
Study 15196292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 60
Study 11602853 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg, intravenously on days 0 and 4)
Number of subjects: 340
Study 11602853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 11602853 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 340
Study 9870123 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited echocardiograms
Number of subjects: 0
Study 9870123 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiograms
Number of subjects: 0
Study 8078710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque)
Number of subjects: 59
Study 8078710 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate (Isopaque)
Number of subjects: 59
Study 2576767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 1012
Study 2576767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and somatostatin
Number of subjects: 1012
Study 2576767 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 1012
Study 2576767 — intervention group
Group type: COMPARATOR
Intervention: Anti-acids (first group)
Number of subjects: 1012
Study 2576767 — intervention group
Group type: COMPARATOR
Intervention: Anti-acids (second group)
Number of subjects: 1012
Study 899874 — intervention group
Group type: EXPERIMENTAL
Intervention: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken with a standardized breakfast meal
Number of subjects: 8
Study 899874 — intervention group
Group type: COMPARATOR
Intervention: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken on an empty stomach
Number of subjects: 8
Study 899874 — intervention group
Group type: EXPERIMENTAL
Intervention: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone)
Number of subjects: 8
Study 30642320 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation teaching with standardized patients
Number of subjects: 157
Study 30642320 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods
Number of subjects: 157
Study 28870473 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob snack
Number of subjects: 50
Study 28870473 — intervention group
Group type: COMPARATOR
Intervention: Chocolate cookie
Number of subjects: 50
Study 25575246 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroEclipse II BAN nebulizer with 30-second inhalation
Number of subjects: 32
Study 25575246 — intervention group
Group type: COMPARATOR
Intervention: EW nebulizer with 30-second inhalation
Number of subjects: 32
Study 25575246 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroEclipse II BAN nebulizer with 20-second inhalation
Number of subjects: 32
Study 25575246 — intervention group
Group type: COMPARATOR
Intervention: EW nebulizer with 20-second inhalation
Number of subjects: 32
Study 23512743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 192
Study 23512743 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-exercise (E)
Number of subjects: 192
Study 23512743 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 192
Study 21317179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 32000
Study 21317179 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 32000
Study 18256842 — intervention group
Group type: EXPERIMENTAL
Intervention: Macugen®
Number of subjects: 0
Study 18256842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucentis®
Number of subjects: 0
Study 18256842 — intervention group
Group type: EXPERIMENTAL
Intervention: Avastin®
Number of subjects: 0
Study 16945217 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial color-coded ultrasound
Number of subjects: 52
Study 16945217 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial duplex and Doppler ultrasound
Number of subjects: 52
Study 14508127 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic Porcine Secretin (SPS)
Number of subjects: 30
Study 14508127 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic Human Secretin (SHS)
Number of subjects: 30
Study 14508127 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic forms of secretin
Number of subjects: 30
Study 14508127 — intervention group
Group type: COMPARATOR
Intervention: Biologic Porcine Secretin (BPS)
Number of subjects: 30
Study 11155785 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions for problem drinking
Number of subjects: 0
Study 9126090 — intervention group
Group type: EXPERIMENTAL
Intervention: Li 'no‐scalpel' method
Number of subjects: 256
Study 9126090 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 256
Study 8257225 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drainage (n = 42)
Number of subjects: 81
Study 8257225 — intervention group
Group type: COMPARATOR
Intervention: Nondrainage (n = 39)
Number of subjects: 81
Study 8257225 — intervention group
Group type: EXPERIMENTAL
Intervention: Major liver resection (both groups)
Number of subjects: 81
Study 8257225 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor liver resection (both groups)
Number of subjects: 81
Study 3898920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose intravenous infusion of lidocaine (2 mg/kg) for 24 hours after surgery
Number of subjects: 20
Study 3898920 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 31767935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 31
Study 31767935 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 29624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n=33)
Number of subjects: 65
Study 29624641 — intervention group
Group type: COMPARATOR
Intervention: Stretching group (n=32)
Number of subjects: 65
Study 27626084 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory lateralization training for 6 weeks (12 sessions)
Number of subjects: 60
Study 27626084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 24989775 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL-021 at 0.96 mg kg(‐1) h(‐1) for 1 h
Number of subjects: 30
Study 24989775 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL-021
Number of subjects: 30
Study 24989775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22527222 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI‐1 4G/5G genotype
Number of subjects: 136
Study 22527222 — intervention group
Group type: EXPERIMENTAL
Intervention: Other PAI‐1 genotypes (4G/4G and 5G/5G)
Number of subjects: 136
Study 22527222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PAI‐1 variants with known genetic thrombophilias
Number of subjects: 136
Study 22527222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin (G20210A) genotype
Number of subjects: 136
Study 20129567 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 354
Study 18847647 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ileocolic resection (LC)
Number of subjects: 56
Study 18847647 — intervention group
Group type: COMPARATOR
Intervention: Open ileocolic resection (OC)
Number of subjects: 56
Study 15241749 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 18
Study 15241749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12422292 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Sense device measuring blood glucose from the forearm
Number of subjects: 66
Study 12422292 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Sense device measuring blood glucose from the fingertip
Number of subjects: 66
Study 9649904 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis using the least-squares method
Number of subjects: 20
Study 9649904 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evaluation
Number of subjects: 20
Study 9649904 — intervention group
Group type: COMPARATOR
Intervention: Reference values for healthy women
Number of subjects: 20
Study 9649904 — intervention group
Group type: EXPERIMENTAL
Intervention: Segment 3 as a reference
Number of subjects: 20
Study 9649904 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different methods of 'normalization'
Number of subjects: 20
Study 9649904 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and quantitative analysis agreement
Number of subjects: 20
Study 7855691 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg daily acenocoumarin
Number of subjects: 258
Study 7855691 — intervention group
Group type: COMPARATOR
Intervention: 2 mg daily acenocoumarin
Number of subjects: 258
Study 2766661 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (100 mg twice daily for 10 days)
Number of subjects: 20
Study 2766661 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 20
Study 2766661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (after potassium canrenoate administration)
Number of subjects: 20
Study 948717 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation of the vas deferens with 40 ml of sterile water on each side
Number of subjects: 59
Study 948717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 59
Study 31899473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 90
Study 31899473 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 90
Study 31899473 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 90
Study 31595565 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (100 mg twice daily)
Number of subjects: 14
Study 31595565 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg three times daily)
Number of subjects: 14
Study 31595565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27806440 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided resections
Number of subjects: 94
Study 27806440 — intervention group
Group type: COMPARATOR
Intervention: Right-sided resections
Number of subjects: 94
Study 26689783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice daily)
Number of subjects: 0
Study 26689783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone
Number of subjects: 0
Study 26689783 — intervention group
Group type: COMPARATOR
Intervention: Standard care (aspirin alone or aspirin and clopidogrel)
Number of subjects: 0
Study 24699093 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium contrast agent administration
Number of subjects: 20
Study 24699093 — intervention group
Group type: COMPARATOR
Intervention: No gadolinium (matched control group)
Number of subjects: 20
Study 24699093 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium contrast agent administration (MS group)
Number of subjects: 20
Study 22563639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 128
Study 22563639 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 128
Study 22563639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)
Number of subjects: 128
Study 20185560 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day antibiotic therapy
Number of subjects: 0
Study 20185560 — intervention group
Group type: COMPARATOR
Intervention: 14-day antibiotic therapy
Number of subjects: 0
Study 17344356 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 126
Study 16039370 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with dorsal plating
Number of subjects: 0
Study 16039370 — intervention group
Group type: COMPARATOR
Intervention: External fixation with K-wires and mini-open reduction
Number of subjects: 0
Study 11507925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate-containing dentifrice
Number of subjects: 94
Study 11507925 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-based high abrasive dentifrice
Number of subjects: 94
Study 11507925 — intervention group
Group type: COMPARATOR
Intervention: Lower abrasive control dentifrice
Number of subjects: 94
Study 10327902 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg, adjustable from 5 mg to 20 mg)
Number of subjects: 139
Study 10327902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 10327902 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 139
Study 7492113 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine plus clindamycin
Number of subjects: 100
Study 7492113 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 100
Study 1759540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + GH + GHRH
Number of subjects: 20
Study 1759540 — intervention group
Group type: COMPARATOR
Intervention: GH + GHRH
Number of subjects: 20
Study 1759540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + GH + GHRH in group B
Number of subjects: 20
Study 1759540 — intervention group
Group type: COMPARATOR
Intervention: GH + GHRH in group A
Number of subjects: 20
Study 1759540 — intervention group
Group type: COMPARATOR
Intervention: GH + GHRH in group B
Number of subjects: 20
Study 6274471 — intervention group
Group type: EXPERIMENTAL
Intervention: suloctidil 300 mg per day
Number of subjects: 40
Study 6274471 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 30756475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 23
Study 30756475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kPa stress
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 kPa stress
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 kPa stress
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 kPa stress
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 kPa stress
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing subjects (G)
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-growing subjects (NG)
Number of subjects: 46
Study 28643922 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of G vs NG
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress magnitude
Number of subjects: 46
Study 28643922 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal applied stresses
Number of subjects: 46
Study 26066915 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Number of subjects: 234
Study 26066915 — intervention group
Group type: COMPARATOR
Intervention: Assessment alone
Number of subjects: 234
Study 23350589 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocancellous allograft block with rhPDGF‐BB
Number of subjects: 16
Study 23350589 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous allograft block with saline solution
Number of subjects: 16
Study 23350589 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard guided bone regeneration with rhPDGF‐BB
Number of subjects: 16
Study 23350589 — intervention group
Group type: COMPARATOR
Intervention: Standard guided bone regeneration with saline solution
Number of subjects: 16
Study 22732511 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin (1.5 g/kgbw at diagnosis and 1 g/kgbw at day 3); n=56
Number of subjects: 110
Study 22732511 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin; n=56
Number of subjects: 110
Study 22732511 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone; n=54
Number of subjects: 110
Study 20083527 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 133
Study 20083527 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 133
Study 16862634 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer health education intervention
Number of subjects: 218
Study 16862634 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional expression intervention
Number of subjects: 218
Study 16862634 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 218
Study 16862634 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (health education, emotional expression, control)
Number of subjects: 218
Study 16862634 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 218
Study 16143188 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone suppressive therapy (THST)
Number of subjects: 609
Study 16143188 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 609
Study 16143188 — intervention group
Group type: COMPARATOR
Intervention: Long-term treatment (5 years)
Number of subjects: 609
Study 16143188 — intervention group
Group type: COMPARATOR
Intervention: THST withdrawal
Number of subjects: 609
Study 12403182 — intervention group
Group type: EXPERIMENTAL
Intervention: Active modalities (various treatments)
Number of subjects: 2104
Study 12403182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning appliance therapy
Number of subjects: 2104
Study 12403182 — intervention group
Group type: COMPARATOR
Intervention: Flat plane splint therapy
Number of subjects: 2104
Study 12403182 — intervention group
Group type: COMPARATOR
Intervention: Untreated TMD patients
Number of subjects: 2104
Study 10453830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 400 mg orally followed by a single oral dose of 400 microg misoprostol 48 hours later (n = 60)
Number of subjects: 122
Study 10453830 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n = 62)
Number of subjects: 122
Study 10453830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 122
Study 7805235 — intervention group
Group type: EXPERIMENTAL
Intervention: Zankiren HCl (10 to 250 mg)
Number of subjects: 24
Study 2179974 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptylinoxide
Number of subjects: 32
Study 2179974 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 32
Study 7250172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of sotalol and hydrochlorothiazide (6.4:1 ratio)
Number of subjects: 30
Study 31526257 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model including stage, two bone marrow texture features, one tumor with penumbra texture feature, and two penumbra texture features.
Number of subjects: 227
Study 31526257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully integrated model with pretreatment FDG PET texture features.
Number of subjects: 227
Study 31526257 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary score stratifying patients into high and low risk of poor outcome.
Number of subjects: 227
Study 28138781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - additional feedback session based on a knowledge test
Number of subjects: 100
Study 28138781 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - routine preoperative patient education only
Number of subjects: 100
Study 28138781 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IG and CG)
Number of subjects: 100